India's ₹20,000-crore cardiac drug market is set to witness a price war as Glenmark Pharmaceuticals on Monday launched a generic version of Novartis' heart-failure drug.
Glenmark's sacubitril-valsartan tablets Sacu V would be priced between 19 and 35 per tablet.
Novartis' Vymada, a fixed-dose combination of sacubitril-valsartan went off-patent on January 16.
Sheetal Sapale, president (marketing), pharma market research firm AIOCDAWACS, said that at least 40 more brands were expected to be launched in this category, leading to a price erosion of at least 50 per cent.
JB Pharma had acquired the Azmar brand from Novartis, Switzerland, for the India region for ₹246 crore in April 2022. In December 2022, JB Pharma slashed.
This story is from the January 18, 2023 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the January 18, 2023 edition of Business Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Brokerages bullish on ICICI Bank stock after Q4 results
Bank's market cap zoomed past 8 trillion mark and settled at ₹8.14 trillion
Choose Aadhaar-based KYC: Once done, you may invest across fund houses
Keep Aadhaar, registered mobile number and scanned documents handy before starting online procedure
Sebi probing Linde India for RPT violation
The Securities and Exchange Board of India (Sebi) on Monday directed Linde India to comply with the norms of materiality thresholds for future related party transactions (RPTS) based on the aggregate value of transactions, amid an ongoing investigation by the regulator.
Hopes of universal bank tag lift AU SFB
Shares of AU Small Finance Bank (SFB) rallied more than 6 per cent on Monday after analysts said the lender meets all eligibility criteria laid down by the Reserve Bank of India (RBI) for obtaining a universal banking licence.
Silver ETF AUM tops ₹5,000 cr
Last month, Gold ETF AUM had topped ₹30,000 crore
Street disappointed with SBI Card's Q4 performance
SBI Cards & Payment Services reported mixed results for the January-March quarter (Q4) of FY24.
Fee outgo: BSE mcap plunges by ₹6,000 cr
Analysts see price hike in options segment to offset costs
Backed by banking stocks, benchmarks gain 1%
The Sensex and the Nifty 50 on Monday gained over 1 per cent each, driven by sharp increases in banking stocks following better-thanexpected quarterly profits from index heavyweight ICICI Bank.
Tone and substance
Subtle shifts in the texture of Sino-US ties
India's West Asia security dynamics
Despite its stakes in the region, its policy doesn't aim for long-term regional stability
